Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × mCRPC × enzalutamide × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 25 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neoplasms 3 Neoplasm Metastasis 3 Prostatic Neoplasms, Castration-Resistant 2 Prostate Cancer Metastatic 2 Metastatic Hormone Sensitive Prostate Cancer 2 mCRPC 1 Recurrence 1 Prostatic Diseases 1 Patient Preference 1 Metastatic Castration-resistent Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer 1 Genital Diseases, Male 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡